


## Thalidomide-NH-C8-NH2 hydrochloride

<b>Cat. No.:</b>	HY-138846A
<b>CAS No.:</b>	2446474-06-0
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>29</sub> ClN <sub>4</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	436.93
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Thalidomide-NH-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Cereblon
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA